Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
about
The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.CT-P13: design, development, and place in therapyEffectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.The Role of Biosimilars in Inflammatory Bowel Disease.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Comparative effectiveness of the biosimilar CT-P13.A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
P2860
Q30397234-C397134C-FAFC-4995-87C9-7ABB6F298C8EQ33803728-1997B10A-9EFE-47C0-9D4F-64BED025049CQ33843746-0713EEA9-157E-4A66-8F1C-CCEA5ED189F0Q37540190-1B7BA536-FED5-4788-A791-C540383952CCQ38977625-4163D6EF-F090-46AB-B934-BC283B9BC52DQ38994573-C71DEB13-1EF8-4343-B1BE-5319C1E0921DQ39018436-0601CBFC-9267-4BCD-8438-33AE2A65A003Q39051341-861AF89A-FC9F-4B3D-92C7-46AC00C89BEAQ39152159-686C5951-407D-4060-A3A4-2A21C8E521D2Q39359495-6DF5EF41-7F79-4CE7-A4AC-862FB4CCF5E5Q47418286-8D60497C-5C75-46D0-A692-862E82C2D241Q48189523-16D90B2B-EA58-4ACD-B24B-1DA618114213Q48217871-D2368AFB-5026-49A4-B95A-09ABF0464D1CQ50073683-573F8740-F83E-47C1-B4CD-45A2AC966B8BQ51280643-AB7FE383-0CE7-4377-9950-CC1CE2A86575
P2860
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@en
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@nl
type
label
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@en
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@nl
prefLabel
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@en
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@nl
P2093
P2860
P1476
Clinical monitoring: inflixima ...... isease and ulcerative colitis.
@en
P2093
František Pešek
Jana Koželuhová
Julius Špičák
Lucie Bartůsková
Luděk Bouchner
Marek Beneš
Martin Pešta
Martin Wasserbauer
Martina Bojková
P2860
P304
P356
10.3109/00365521.2016.1149883
P577
2016-03-22T00:00:00Z